Site-specific expression of amine oxidases in breast cancer metastases

Yoon Jin Cha, Woo Hee Jung, Ja Seung Koo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We aimed to evaluate the expression of amine oxidase-related proteins in metastatic breast cancer tissue and determine its clinical implication. A tissue microarray was constructed from a total of 126 metastatic breast tumors (31 bone metastases (24.6%), 36 brain metastases (28.6%), 11 liver metastases (8.7%), and 48 lung metastases (38.1%)). Immunohistochemical staining for amine oxidase-related proteins (lysyl oxidase, diamine oxidase, and monoamine oxidase A and B) was performed. In metastatic breast cancer tissue, lysyl oxidase (p = 0.001), tumoral diamine oxidase (p = 0.003), stromal diamine oxidase (p = 0.047), and stromal monoamine oxidase B (p = 0.002) were differentially expressed in different metastatic sites. Bone metastases showed low expression of lysyl oxidase, tumoral diamine oxidase, and stromal diamine oxidase. We observed high expression of lysyl oxidase in brain metastases, tumoral diamine oxidase in liver metastases, stromal diamine oxidase in lung metastases, and stromal monoamine oxidase B in bone metastases. Lysyl oxidase positivity was associated with progesterone receptor negativity (p = 0.001), and monoamine oxidase A positivity was associated with human epidermal growth factor receptor-2 negativity (p = 0.003) and the luminal A subtype (p = 0.003). On univariate analysis shorter overall survival was associated with stromal diamine oxidase negativity (p = 0.008), especially in lung metastases (p = 0.025), and stromal monoamine oxidase B positivity (p < 0.001). Stromal monoamine oxidase B positivity was an independent prognostic factor for shorter overall survival in multivariate Cox analysis (hazard ratio, 4.069; 95% confidence interval, 1.649–10.04; p = 0.002). Finally, in metastatic breast cancer, amine oxidase-related proteins were differentially expressed in a manner specific to metastatic site, and stromal monoamine oxidase B expression was correlated with prognosis.

Original languageEnglish
JournalTumor Biology
Volume40
Issue number5
DOIs
Publication statusPublished - 2018 May 1

Fingerprint

Amine Oxidase (Copper-Containing)
Amines
Monoamine Oxidase
Oxidoreductases
Protein-Lysine 6-Oxidase
Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
Lung
Proteins
Liver
Brain
Progesterone Receptors
Multivariate Analysis
Confidence Intervals
Staining and Labeling

All Science Journal Classification (ASJC) codes

  • Cancer Research

Cite this

@article{d14c2e924aca4bb68a9e5efbed092096,
title = "Site-specific expression of amine oxidases in breast cancer metastases",
abstract = "We aimed to evaluate the expression of amine oxidase-related proteins in metastatic breast cancer tissue and determine its clinical implication. A tissue microarray was constructed from a total of 126 metastatic breast tumors (31 bone metastases (24.6{\%}), 36 brain metastases (28.6{\%}), 11 liver metastases (8.7{\%}), and 48 lung metastases (38.1{\%})). Immunohistochemical staining for amine oxidase-related proteins (lysyl oxidase, diamine oxidase, and monoamine oxidase A and B) was performed. In metastatic breast cancer tissue, lysyl oxidase (p = 0.001), tumoral diamine oxidase (p = 0.003), stromal diamine oxidase (p = 0.047), and stromal monoamine oxidase B (p = 0.002) were differentially expressed in different metastatic sites. Bone metastases showed low expression of lysyl oxidase, tumoral diamine oxidase, and stromal diamine oxidase. We observed high expression of lysyl oxidase in brain metastases, tumoral diamine oxidase in liver metastases, stromal diamine oxidase in lung metastases, and stromal monoamine oxidase B in bone metastases. Lysyl oxidase positivity was associated with progesterone receptor negativity (p = 0.001), and monoamine oxidase A positivity was associated with human epidermal growth factor receptor-2 negativity (p = 0.003) and the luminal A subtype (p = 0.003). On univariate analysis shorter overall survival was associated with stromal diamine oxidase negativity (p = 0.008), especially in lung metastases (p = 0.025), and stromal monoamine oxidase B positivity (p < 0.001). Stromal monoamine oxidase B positivity was an independent prognostic factor for shorter overall survival in multivariate Cox analysis (hazard ratio, 4.069; 95{\%} confidence interval, 1.649–10.04; p = 0.002). Finally, in metastatic breast cancer, amine oxidase-related proteins were differentially expressed in a manner specific to metastatic site, and stromal monoamine oxidase B expression was correlated with prognosis.",
author = "Cha, {Yoon Jin} and Jung, {Woo Hee} and Koo, {Ja Seung}",
year = "2018",
month = "5",
day = "1",
doi = "10.1177/1010428318776822",
language = "English",
volume = "40",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "5",

}

Site-specific expression of amine oxidases in breast cancer metastases. / Cha, Yoon Jin; Jung, Woo Hee; Koo, Ja Seung.

In: Tumor Biology, Vol. 40, No. 5, 01.05.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Site-specific expression of amine oxidases in breast cancer metastases

AU - Cha, Yoon Jin

AU - Jung, Woo Hee

AU - Koo, Ja Seung

PY - 2018/5/1

Y1 - 2018/5/1

N2 - We aimed to evaluate the expression of amine oxidase-related proteins in metastatic breast cancer tissue and determine its clinical implication. A tissue microarray was constructed from a total of 126 metastatic breast tumors (31 bone metastases (24.6%), 36 brain metastases (28.6%), 11 liver metastases (8.7%), and 48 lung metastases (38.1%)). Immunohistochemical staining for amine oxidase-related proteins (lysyl oxidase, diamine oxidase, and monoamine oxidase A and B) was performed. In metastatic breast cancer tissue, lysyl oxidase (p = 0.001), tumoral diamine oxidase (p = 0.003), stromal diamine oxidase (p = 0.047), and stromal monoamine oxidase B (p = 0.002) were differentially expressed in different metastatic sites. Bone metastases showed low expression of lysyl oxidase, tumoral diamine oxidase, and stromal diamine oxidase. We observed high expression of lysyl oxidase in brain metastases, tumoral diamine oxidase in liver metastases, stromal diamine oxidase in lung metastases, and stromal monoamine oxidase B in bone metastases. Lysyl oxidase positivity was associated with progesterone receptor negativity (p = 0.001), and monoamine oxidase A positivity was associated with human epidermal growth factor receptor-2 negativity (p = 0.003) and the luminal A subtype (p = 0.003). On univariate analysis shorter overall survival was associated with stromal diamine oxidase negativity (p = 0.008), especially in lung metastases (p = 0.025), and stromal monoamine oxidase B positivity (p < 0.001). Stromal monoamine oxidase B positivity was an independent prognostic factor for shorter overall survival in multivariate Cox analysis (hazard ratio, 4.069; 95% confidence interval, 1.649–10.04; p = 0.002). Finally, in metastatic breast cancer, amine oxidase-related proteins were differentially expressed in a manner specific to metastatic site, and stromal monoamine oxidase B expression was correlated with prognosis.

AB - We aimed to evaluate the expression of amine oxidase-related proteins in metastatic breast cancer tissue and determine its clinical implication. A tissue microarray was constructed from a total of 126 metastatic breast tumors (31 bone metastases (24.6%), 36 brain metastases (28.6%), 11 liver metastases (8.7%), and 48 lung metastases (38.1%)). Immunohistochemical staining for amine oxidase-related proteins (lysyl oxidase, diamine oxidase, and monoamine oxidase A and B) was performed. In metastatic breast cancer tissue, lysyl oxidase (p = 0.001), tumoral diamine oxidase (p = 0.003), stromal diamine oxidase (p = 0.047), and stromal monoamine oxidase B (p = 0.002) were differentially expressed in different metastatic sites. Bone metastases showed low expression of lysyl oxidase, tumoral diamine oxidase, and stromal diamine oxidase. We observed high expression of lysyl oxidase in brain metastases, tumoral diamine oxidase in liver metastases, stromal diamine oxidase in lung metastases, and stromal monoamine oxidase B in bone metastases. Lysyl oxidase positivity was associated with progesterone receptor negativity (p = 0.001), and monoamine oxidase A positivity was associated with human epidermal growth factor receptor-2 negativity (p = 0.003) and the luminal A subtype (p = 0.003). On univariate analysis shorter overall survival was associated with stromal diamine oxidase negativity (p = 0.008), especially in lung metastases (p = 0.025), and stromal monoamine oxidase B positivity (p < 0.001). Stromal monoamine oxidase B positivity was an independent prognostic factor for shorter overall survival in multivariate Cox analysis (hazard ratio, 4.069; 95% confidence interval, 1.649–10.04; p = 0.002). Finally, in metastatic breast cancer, amine oxidase-related proteins were differentially expressed in a manner specific to metastatic site, and stromal monoamine oxidase B expression was correlated with prognosis.

UR - http://www.scopus.com/inward/record.url?scp=85047291819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047291819&partnerID=8YFLogxK

U2 - 10.1177/1010428318776822

DO - 10.1177/1010428318776822

M3 - Article

C2 - 29775160

AN - SCOPUS:85047291819

VL - 40

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 5

ER -